
Q32 Bio Inc. — Investor Relations & Filings
Q32 Bio Inc. is a clinical-stage biotechnology company developing therapies to restore healthy immune balance in patients with autoimmune and inflammatory diseases. The company's therapeutic approach targets powerful regulators of both the innate and adaptive immune systems. Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from both interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). The candidate is currently being evaluated in a Phase 2 program for the treatment of alopecia areata.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-27 | English | |
| 10-Q - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | |
| 8-K - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | |
| ARS - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | |
| DEF 14A - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | |
| 424B5 - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-24 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47843637 | 8-K | 2026-05-27 | English | ||
| 41350292 | 10-Q - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | ||
| 41346460 | 8-K - Q32 Bio Inc. (0001661998) (Filer) | 2026-05-05 | English | ||
| 39072013 | ARS - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | ||
| 39069697 | DEF 14A - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-30 | English | ||
| 36267508 | 424B5 - Q32 Bio Inc. (0001661998) (Filer) | 2026-04-24 | English | ||
| 33003133 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 33003135 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 33003131 | 4 - Q32 Bio Inc. (0001661998) (Issuer) | 2026-03-21 | English | ||
| 32896138 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 32896139 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 32896140 | 4 - Q32 BIO INC. (0001661998) (Filer) | 2026-02-27 | English | ||
| 31187430 | 8-K Filing | 2026-02-17 | English | ||
| 31187392 | 424B5 Filing | 2026-02-17 | English | ||
| 31187419 | 4 Filing | 2026-01-30 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CHAMPIONS ONCOLOGY, INC.
A CRO providing end-to-end solutions to accelerate oncology…
|
CSBR | US | Professional, scientific and te… |
|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
A contract research organization supporting drug discovery …
|
CRL | US | Professional, scientific and te… |
|
ChemPartner PharmaTech Co., Ltd.
Global CRO and CDMO providing integrated drug discovery and…
|
300149 | CN | Professional, scientific and te… |
|
CHIMERIC THERAPEUTICS LIMITED
Clinical-stage cell therapy company developing CAR T and NK…
|
CHM | AU | Professional, scientific and te… |
|
China National Electric Apparatus Research Institute Co., Ltd.
R&D institution for electrical and electronics testing, equ…
|
688128 | CN | Professional, scientific and te… |
|
Chiome Bioscience Inc.
Clinical-stage biotech company developing antibody-based th…
|
4583 | JP | Professional, scientific and te… |
|
CHITOGENX INC
Clinical stage regenerative medicine company focused on nov…
|
CHGX | CA | Professional, scientific and te… |
|
Chordate Medical Holding AB
Develops a patented, drug-free neuromodulation treatment fo…
|
CMH | SE | Professional, scientific and te… |
|
Chordia Therapeutics,Inc
Clinical-stage biotech developing novel cancer therapies ta…
|
190A | JP | Professional, scientific and te… |
|
Cibus, Inc.
Develops and licenses plant traits using non-GMO precision …
|
CBUS | US | Professional, scientific and te… |
Q32 Bio Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34891/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34891 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34891 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34891 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34891}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Q32 Bio Inc. (id: 34891)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.